ZOLL Launches Next Generation MCT Solution, Shown to Improve Patient Management Decisions in Largest Ever MCT Trial

CONTACT:

Caitlyn Doyle

ZOLL Medical Corporation

ZOLL LAUNCHES NEXT GENERATION MCT SOLUTION, SHOWN TO IMPROVE PATIENT MANAGEMENT DECISIONS IN LARGEST EVER MCT TRIAL

The ZOLL Arrhythmia Management System (AMS) mobile cardiac telemetry (MCT) solution adds biometric data to traditional MCT data, helping physicians make more informed treatment plans

March 21, 2022 — CHELMSFORD, MASS. — ZOLL^® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced the launch of the ZOLL Arrhythmia Management System (AMS). ZOLL AMS adds biometric data (heart rate, activity, respiratory rate, and body posture) to the ECG information provided by traditional MCT devices. A new study demonstrates that ZOLL AMS helps physicians make more informed patient treatment plans.

The MAPS Trial (Mobile Cardiac Telemetry and Advanced Multi-Parameter Monitoring in Patients Wearing a Novel Device Trial) is the largest prospective, multicenter MCT study ever conducted, enrolling 583 patients. The endpoints of the trial included an evaluation of the association of biometric data with arrhythmias and symptoms and the demonstrated clinical utility provided by adding biometric data to traditional MCT event and end-of-use reports. The trial met all endpoints and is the first MCT study to document, in a real-world setting, statistically significant relationships between arrhythmias and biometric parameters and between patient symptoms and biometrics.

Physicians first reviewed traditional MCT reports for all events and patients and made treatment plan recommendations. Physicians then reviewed the ZOLL AMS reports for the same events and patients, which included biometric data along with traditional MCT data. The addition of ZOLL AMS biometric data and insights led to treatment plan changes for more than 60% of patients compared to traditional MCT and included adjustments to lifestyle, medications, and follow-up plans. The results demonstrate the significant impact of these data on patient care decisions.

"The patient biometric data available from ZOLL AMS represents a leap forward in MCT technology," said Robert L. Salazar, M.D., F.A.C.C., Texas Cardiology Associates of Houston, an investigator on the MAPS Trial. "ZOLL AMS data enhance the clinical picture by providing context to arrhythmic or symptomatic events. For example, a patient experiencing bradycardia while exercising would require a vastly different care plan than if they experience bradycardia while napping. With ZOLL AMS, we can get that level of clarity."

With ZOLL AMS, physicians receive timely event-based reports, as well as comprehensive end-of-use reports with clinically relevant data, including sleep, activity, respiratory rate, and patient status, to help assess a patient’s broader health and wellness and guide meaningful treatment decisions.

"ZOLL AMS is the next generation of MCT with a feature set that significantly advances cardiac patient monitoring," said Jason T. Whiting, President of ZOLL Cardiac Management Solutions. "ZOLL AMS now provides physicians with meaningful clinical value for all MCT patients, including those who do not experience an arrhythmia or symptoms. In the MAPS Trial, physicians reported that in patients who had no reported arrhythmias or symptoms, ZOLL AMS data helped them better understand the patient status compared to traditional ECG-only MCT data."

The full results of the MAPS Trial are anticipated to be published in the spring of 2022. To learn more about the MAPS Trial, visit https://clinicaltrials.gov/ct2/show/NCT04754204.

ZOLL AMS is initially available in select U.S. markets followed by expansion throughout the U.S. in the coming months.

About ZOLL Medical Corporation

ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 40,000 employees around the world, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit www.asahi-kasei.com.

Copyright © 2022 ZOLL Medical Corporation. All rights reserved. ZOLL is a registered trademark of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.

###